Lantheus Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lantheus Holdings, Inc.
Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Kadmon Chooses RTOR For Belumosudil; NDAs For Novel Imaging Agents And Liquid Anticonvulsants
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc.